Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Clinical Trial Using BR55 Targeted Ultrasound Contrast Agent in the Detection of Prostate Cancer by Molecular Imaging of VEGFR2

NCT01253213 is registered in ClinicalTrials.gov with Bracco Diagnostics, Inc as lead sponsor.

NCT NCT01253213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01253213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Clinical Trial Using BR55 Targeted Ultrasound Contrast Agent in the Detection of Prostate Cancer by Molecular Imaging of VEGFR2
Lead sponsor
Bracco Diagnostics, Inc
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2010
Completion date
December 31, 2012
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer